Financial Summary (All financials)
In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
Revenues | 852.0 | 753.0 | 727.0 | 13,146.0 | 9,708.0 | 8,793.0 | 4,861.0 | 4,651.0 |
Revenue growth | 13.1% | 3.6% | -94.5% | 35.4% | 10.4% | 80.9% | 4.5% | 9.1% |
Cost of goods sold | 1,705.0 | 1,433.0 | 1,279.0 | 1,200.0 | 1,141.0 | 1,043.0 | 1,013.0 | 994.0 |
Gross profit | -853.0 | -680.0 | -552.0 | 11,946.0 | 8,567.0 | 7,750.0 | 3,848.0 | 3,657.0 |
Gross margin | -100.1% | -90.3% | -75.9% | 90.9% | 88.2% | 88.1% | 79.2% | 78.6% |
Selling, general and administrative | | | | | | | | |
Sales and marketing | 562.0 | 517.0 | 475.0 | 440.0 | 415.0 | 389.0 | 378.0 | 374.0 |
Research and development | 345.0 | 314.0 | 311.0 | 299.0 | 284.0 | 274.0 | 267.0 | 334.0 |
EBITA | 3,739.0 | 1,380.0 | 1,978.0 | 1,632.0 | 7,595.0 | 6,819.0 | 881.0 | 863.0 |
EBITA margin | 438.8% | 183.3% | 272.1% | 12.4% | 78.2% | 77.6% | 18.1% | 18.6% |
Amortization of intangibles | 20.0 | 18.0 | 13.0 | 11.0 | 11.0 | 6.0 | | |
EBIT | 3,719.0 | 1,362.0 | 1,965.0 | 1,621.0 | 7,584.0 | 6,813.0 | 881.0 | 863.0 |
EBIT margin | 436.5% | 180.9% | 270.3% | 12.3% | 78.1% | 77.5% | 18.1% | 18.6% |
Pre-tax income | 3,855.0 | 1,414.0 | 1,967.0 | 1,622.0 | 1,507.0 | 1,581.0 | 1,393.0 | 1,246.0 |
Income taxes | 790.0 | 328.0 | 246.0 | 359.0 | 581.0 | 470.0 | 496.0 | 321.0 |
Tax rate | 20.5% | 23.2% | 12.5% | 22.1% | 38.6% | 29.7% | 35.6% | 25.8% |
Earnings from continuing ops | 3,003.0 | 1,085.0 | 1,715.0 | 1,263.0 | 926.0 | 1,111.0 | 897.0 | 925.0 |
Earnings from discontinued ops | 0.0 | 0.0 | 0.0 | | | | | |
Net income | 3,003.0 | 1,085.0 | 1,715.0 | 1,263.0 | 929.0 | 1,067.0 | 1,289.0 | 1,150.0 |
Net margin | 352.5% | 144.1% | 235.9% | 9.6% | 9.6% | 12.1% | 26.5% | 24.7% |
|
Diluted EPS | $8.22 | $2.88 | $4.34 | $2.95 | $2.03 | $2.30 | $1.86 | $1.92 |
Shares outstanding (diluted) | 365.2 | 377.1 | 395.4 | 427.7 | 455.4 | 482.2 | 482.9 | 481.9 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|